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Depression, anxiety and substance use
drug-dependent populations,3 methamphet-
amine directly affects monoamine regulation
within the brain, producing a pseudodepres-
sive state that encompasses many of the
features of ajor depression (ie, low mood,
anhedonia, fatigue, sleep disturbance, appe-
tite changes, lack of motivation, restlessness,
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Objective:  To determine the prevalence of major depression among people entering 
treatment for methamphetamine use.
Design, setting and participants:  The study was a cross-sectional survey involving 
41 specialised drug and alcohol treatment agencies in Brisbane and Sydney. Services 
provided by these agencies included residential rehabilitation, detoxification and 
selling. Participants were 400 people entering treatment for methamphetamine use 
were recruited from participating treatment agencies between January 2006 and 
mber 2007. Participants underwent a structured, face-to-face, 1.5-hour interview. 
ssment instruments included the Composite International Diagnostic Interview and 
hort Form 12.
 outcome measure:  Diagnosis of a major depressive episode in the year prior to 
tudy.
Results:  The prevalence of major depression in the year prior to the study was 40% (95% 
CI, 35%–44%). A noteworthy post-hoc observation was that a further 44% of participants 
met the symptom criteria for major depression but were excluded from a diagnosis
because their symptoms were better accounted for by psychoactive substance use. 
Both major depression and these latter cases of “substance-induced depression” were 
associated with severe symptoms of depression, high levels of disability and suicidal 
ideation.
Conclusion:  Most people entering treatment programs for methamphetamine use
have levels of depression that require clinical management. Making a diagnosis of major 
depression in the context of heavy methamphetamine use is problematic because of 
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substance-induced symptoms of depression.syc
ere
seqP hotic phenomena are often consid-d to be the hallmark psychiatricuelae of methamphetamine use, but
depressive symptoms are far more common
and can be severe and debilitating among
heavy users of the drug.1,2 Although depres-
sion is not an uncommon phenomenon in
irritability and poor concentration).4,5
If left untreated, depression can reduce
adherence to drug treatment, increase the
risk of relapse to stimulant use and elevate
the risk of suicide.6,7 Despite this, there are
no available estimates for the prevalence of
major depression among methamphetamine
users who enter treatment programs. Previ-
ous research has reported high levels of
depressive symptoms among dependent
methamphetamine users,7 and one study
screened for major depression,6 but no stud-
ies have assessed the prevalence of major
depression using a validated psychiatric
assessment instrument. This makes it hard
to determine the extent to which depression
among methamphetamine users requires
clinical management.
The aim of our study was to determine
the prevalence of major depression over the
previous 12 months in a population of
dependent methamphetamine users. We
used data from the baseline phase of the
Australian Methamphetamine Treatment
Evaluation Study, which assessed psychiatric
comorbidity in a cohort of methamphet-
amine users entering specialised drug and
alcohol services within the community.
METHODS
Participants and recruitment
Participants (n = 400) were recruited on
entry to participating drug treatment agen-
cies, which were selected from agencies
contributing data to the Alcohol and Other
Drug Treatment Services National Minimum
Data Set. This includes all publicly funded
government and non-government agencies
that provide specialist treatment services to
people with alcohol and other drug prob-
lems. Agencies providing counselling, resi-
dential rehabilitation and detoxification
were included, but those providing assess-
ment only, case management only or other
services (eg, education) were excluded.
Forty-one agencies were included in the
recruitment pool — 26 in the Sydney region
and 15 in the Brisbane region. These agen-
cies included 15 outpatient counselling
services, 13 residential rehabilitation facili-
ties, 11 detoxification units and two services
that provided both detoxification and resi-
dential rehabilitation.
Participants were eligible if they were
entering treatment with methamphetamine
or amphetamine use as a primary or second-
ary drug problem (78% reported it to be
their primary drug problem). Participants
had to be at least 16 years of age, willing to
do follow-up interviews, and able to under-
stand English. They were excluded if, in the
previous month, they had been incarcer-
ated, had received treatment for their meth-
amphetamine use, or had received any form
of inpatient drug treatment. This exclusion
criterion was necessary to obtain a naturalis-
tic baseline measure of pretreatment meth-
amphetamine use.
Participants were recruited between Janu-
ary 2006 and November 2007. A further
195 prospective participants were screened
but found ineligible, mainly because they
had been in treatment (58%) or incarcerated
(28%) during the previous month, or had
declined participation in the study (10%).
The main treatment modalities received
by participants in the final sample were
residential rehabilitation (n = 211), with-
drawal management (n = 149) and counsel-
ling (n = 40).
All participants were volunteers who pro-
vided informed consent and were reim-
bursed $30 for their time and travel
expenses.
Procedure
Participants took part in a structured, face-
to-face, 1.5-hour interview a median of 4MJA • Volume 195 Number 3 • 1 August 2011 S51
SUPPLEMENTdays after treatment entry (range, 0–32
days). The interview included questions on
demographics (such as age, sex, employ-
ment status, country of birth, prison history,
income, and living arrangement), the Com-
posite International Diagnostic Interview
(CIDI), the Short Form 12 (SF-12) and the
Opiate Treatment Index (OTI).8 All
responses were completed by the inter-
viewer. Interviewers had undergone certi-
fied training in use of the CIDI.
Measures
Major depression
The CIDI was used to establish a diagnosis
of a major depressive episode in the preced-
ing 12 months, based on criteria specified in
the Diagnostic and statistical manual of mental
disorders, 4th edition (DSM-IV).9 The CIDI
is a fully structured, lay-administered inter-
view schedule that has been validated
against clinician-administered psychiatric
interview schedules and is widely used in
epidemiological studies.10 In order to meet
the DSM-IV criteria for a major depressive
episode, five or more symptoms of depres-
sion must have been present during the
same 2-week period and represent a change
in functioning, and one of the symptoms
must be either depressed mood or loss of
interest/pleasure (Criterion A); the symp-
toms must not meet criteria for a mixed
episode (Criterion B); the symptoms must
cause clinically significant distress or
impairment (Criterion C); the symptoms
must not be due to the direct physiological
effects of a substance or medical condition
(Criterion D); and the symptoms must not
be better accounted for by bereavement
(Criterion E).
The CIDI also flagged instances in which
respondents’ symptoms met criteria for
major depression but diagnostic criteria
were not met because the symptoms were
considered to be the result of direct physio-
logical effects of using a substance (Criterion
D). For conciseness, we have referred to this
condition as “substance-induced depres-
sion”. Criterion D was not met if partici-
pants endorsed that depressive symptoms
were “always the result of taking medica-
tion, drugs or alcohol” or if they told a
medical doctor about their depressive symp-
toms and the doctor said that the symptoms
were caused by medication, drugs or alco-
hol. We were unable to assess DSM-IV Crite-
rion B, so participants with a mixed episode
may have been included in the major
depression group.
The severity of major depression was
coded as mild (5–6 symptoms), moderate (7
symptoms) or severe ( 8 symptoms).
Help-seeking
Participants who met DSM-IV criteria for
major depression were asked whether they
had received professional help for their
depression in the previous year, and if so,
whether they felt they had received as much
help as they needed. They were asked about
sources of help they had accessed and the
main source of help received (general practi-
tioner, drug treatment counsellor/worker,
community health centre worker, private/
independent psychologist, private/inde-
pendent psychiatrist, other private counsel-
lor, or other).
Substance use
Methamphetamine dependence was diag-
nosed using the CIDI.8
The number of days of drug use in the
previous month was measured using the
OTI11 (daily substance use was defined as
having used 20 or more days in the previous
month).
Drug use in the previous year was also
assessed for all major drug classes. For each
drug, participants were asked whether they
had used the drug in the previous 12
months, and if so, how often, with possible
response categories being: no use, less than
weekly, weekly, 2 days per week, 3–4 days
per week, or  5 days per week.
A polydrug-use score was calculated
based on the number of other drug classes
used in the previous year (drug classes
included cannabis, heroin, cocaine, ecstasy,
hallucinogens, inhalants, alcohol, tobacco
and benzodiazepines).
Other measures
Physical and mental health were assessed
using the SF-12. Physical or mental
health disability was defined as having a
score below 40 (> 1 SD below the norma-
tive mean) on the physical or mental
health component scales of the SF-12,
respectively.12
Participants’ use of health services in the
previous year was also assessed, including
the number of visits to GPs.
Statistical analyses
Descriptive analyses were based on non-
parametric tests (median comparison tests
for continuous variables and Pearson’s χ2
tests for categorical variables). An explora-
tory post-hoc analysis was undertaken to
examine correlates of major depression and
substance-induced depression. Logistic
regression was used to adjust for covariates.
All tests were two-sided. Significance was set
at P < 0.05. Data were analysed using
STATA/SE software, version 11.1 (Stata-
Corp, College Station, Tex, USA).
RESULTS
Demographic and drug-use 
characteristics
Demographic and drug-use characteristics
of participants are summarised in Box 1.
Participants were typical of methampheta-
mine users entering treatment in Australia,13
with a predominance of single unemployed
males, most of whom (83%) had injected
methamphetamine. The median age was 31
years (range, 16–54 years). Almost all par-
ticipants (97%) met DSM-IV criteria for
methamphetamine dependence.
The reported frequency of methampheta-
mine use over the previous year was typi-
cally 3–4 days per week (39%) or more
often (38%).
Participants had used a median of five
other drug classes in the previous year
(range, 1–9), the most common being
tobacco (96%), alcohol (87%) and cannabis
(87%). Almost half the sample (47%)
reported smoking cannabis on a daily basis
over the previous year, and 21% reported
drinking alcohol at this level. The use of
other drugs in the previous year was also
common (ecstasy [63%], cocaine [48%],
heroin [35%] and inhalants [19%]), but less
than 5% of the sample reported using them
daily.
Prevalence of depression
Forty per cent (95% CI, 35%–44%) of
participants (n = 158) met DSM-IV criteria
for a major depressive episode in the previ-
ous year. Symptoms were usually current
(82% of depressed participants had experi-
enced symptoms in the previous month)
and episodes were usually severe (79% of
the sample). The prevalence of major
depression did not differ significantly by
treatment modality.
A further 44% (95% CI, 39%–49%) of the
sample (n = 176) met the symptom criteria
for major depression (DSM-IV Criterion A),
but were excluded from the diagnosis
because their symptoms were always the
result of substance use (DSM-IV Criterion
D). This substance-induced depression had
a similar symptom profile to major depres-
sion, but with lower levels of suicidal idea-
tion and with fewer participants reportingS52 MJA • Volume 195 Number 3 • 1 August 2011
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weeks or more (Box 2).
Both conditions were associated with
high levels of disability due to poor mental
health, more severe methamphetamine
dependence and polydrug use (Box 2).
Substance-induced depression was signifi-
cantly associated with initiating metham-
phetamine use at a younger age, and major
depression was more common among
women (Box 1).
Impact of polydrug use
Specific polydrug patterns that were associ-
ated with depression were cannabis and ben-
zodiazepine use. After adjustment for severe
methamphetamine dependence and other
demographic factors associated with depres-
sion (Box 1), both cannabis and benzo-
diazepine use remained significantly
associated with major depression (cannabis:
odds ratio [OR], 2.3 [95% CI, 1.2–4.4]; P =
0.013; benzodiazepines: OR, 2.1 [95% CI,
1.1–4.2]; P =0.032) and substance-induced
depression (cannabis: OR, 2.4 [95% CI, 1.2–
4.6]; P = 0.010; benzodiazepines: OR, 2.0
[95% CI, 1.0–4.0]; P = 0.049). The preva-
lence of major depression among participants
who had used cannabis and/or benzodi-
azepines in the previous month was 42%,
compared with 26% among those who had
used neither drug.
Disability
Both major depression and substance-
induced depression were associated with
high levels of mental health disability. Parti-
cipants with major depression were nearly
13 times more likely to report mental health
disability on the SF-12 than those without
depression (OR, 12.5 [95% CI, 5.6–28.1];
P < 0.001), and those with substance-
induced depression had seven times the
likelihood of mental health disability (OR,
7.0 [95% CI, 3.5–13.8]; P < 0.001). These
effects were adjusted for other factors associ-
ated with depression (ie, being female, earl-
ier initiation into methamphetamine use,
more severe methamphetamine dependence
and higher polydrug use) that did not inde-
pendently predict disability (P > 0.05).
Help-seeking for major depression
Fifty-eight per cent of participants with
major depression (n = 91) had received pro-
fessional help for their depression in the
previous year. Of these, only 27% felt they
had received as much help as they needed.
Most participants (76%) who did not receive
any help felt that they needed help.
Participants who received help for depres-
sion cited their main source of help as GPs
(42%), drug treatment professionals (16%),
private psychiatrists (11%), psychologists
(9%) and counsellors (8%). Ninety per cent
of participants with major depression had
seen a GP in the previous year, with a
median number of five visits.
Antidepressant use
About half (53%) of participants who had
experienced a major depressive episode in
the previous year, and 27% of those who
had not, had taken antidepressants. Poly-
drug use among participants who were tak-
ing antidepressant medication was
ubiquitous. Of those who had used antide-
pressant medication in the previous month
(21%), most (69%) had taken antidepres-
sants every day during this time, almost all
(93%) had continued to use methamphet-
amine, and the majority had done so fre-
quently (median, 16 days of use in the
previous month). Most also used cannabis
(79%) and did so on a regular basis
(median, 18 days of use in the previous
month). Alcohol use was also common
(74%), with 21% of users drinking daily
while taking antidepressants.
DISCUSSION
Our findings suggest that clinical levels of
depression are almost ubiquitous among
people entering treatment for methamphet-
amine use, indicating a need for clinical
protocols to manage depression in this con-
text. Four in 10 methamphetamine treat-
ment entrants in the current sample met
DSM-IV criteria for a major depressive epi-
sode in the previous year, and a further 44%
had substance-induced depressive symp-
toms that were similarly severe and dis-
abling. These levels of depression are high,
even when compared with levels in other
drug-dependent populations.3
1 Characteristics of participants with major depression or substance-induced 
depression
Diagnostic group
Total
sample
(N = 400)
No 
depression
(n = 66)
Substance-induced 
depression 
(n = 176)
Major
depression 
(n = 158)
Demographics
Female sex (%) 26 20 19 35*
Median age (years) 31 33 30 31
Unemployed (%) 81 85 82 77
Born outside Australia (%) 14 12 18 9
History of incarceration (%) 39 35 44 34
Married (%) 17 14 16 19
Drug use history 
Median age at first 
methamphetamine use (years)
17 18 16† 17
Median years of 
methamphetamine use 
11 11 11 11
Severe methamphetamine 
dependence‡ (%)
31 17 34* 34*
High polydrug use§ (%) 64 52 66* 67*
Short Form 12
Mental health disability (%) 84 52 87¶ 93¶
Physical health disability (%) 23 21 24 22
* P < 0.05 compared with the no-depression group. † P < 0.01 compared with the no-depression group. 
‡ Above the median of six symptoms of dependence. § Five or more drug classes used in the previous year. 
¶ P < 0.001 compared with the no-depression group. ◆MJA • Volume 195 Number 3 • 1 August 2011 S53
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sion and substance-induced symptoms of
depression was problematic. Whether
existing structured psychiatric assessment
instruments can accurately make this dis-
tinction remains controversial.14-16 The dif-
ferential diagnosis of independent and
substance-induced disorders relies on
respondents having insight into the tempo-
ral relationship between their substance
use and their depressive symptoms, which,
in turn, requires periods of abstinence from
drug use. Long periods of abstinence are a
rarity in populations of heavily dependent
drug users, who, by definition, find it hard
to abstain, and typically engage in almost
daily patterns of polydrug use, oscillating
between intoxication and withdrawal.
Making a diagnosis of depression in the
context of methamphetamine use is parti-
cularly problematic, as many of the drug’s
acute effects (such as reduced appetite and
insomnia) and withdrawal symptoms (such
as anhedonia, depressed mood, hypersom-
nolence and increased appetite) overlap
with the symptoms of depression.17 Partici-
pants in our study may have misattributed
depressive symptoms to drug use, or vice
versa.
GPs were the most common source of
help for depression among methamphet-
amine users, but even so, a large proportion
of methamphetamine users did not receive
help for depression from their GP (or via
other avenues), or did not receive as much
help as they thought they needed. This
finding indicates that there is a substantial
gap in mental health service provision for
dependent methamphetamine users and
that GPs are well placed to provide treat-
ment and referral for this population. The
use of antidepressant medication was com-
mon in this sample of methamphetamine
users, and GPs need to consider the poten-
tial interactions between antidepressant
medication and the range of illicit drugs that
are concurrently consumed by methamphet-
amine users. Particular consideration should
be given to the role of psychosocial interven-
tions for depression (eg, cognitive behaviour
therapy) as an alternative to medication.2,7
There is undoubtedly a range of factors
that contribute to depression among meth-
amphetamine users. Illicit drug use is asso-
ciated with various social and individual risk
factors for depression (eg, social stressors,
poverty, and physical illness such as hepati-
tis C). In our study, concurrent polydrug use
(in particular, use of cannabis and benzodi-
azepines) was significantly associated with
depression, a finding that is consistent with
previous research in this area.1 The relation-
ship between drug use and depression is
likely to be bidirectional, with heavy drug
dependence leading to mood changes and
life stressors that increase the risk of depres-
sion, and people with depression self-medi-
cating with drugs to relieve their depression.
This is particularly likely in the context of
methamphetamine use, because acute intox-
ication with the drug has a potent short-
term antidepressant effect.18
In conclusion, the clinical management of
depression and related suicide risk is imper-
ative within settings that provide treatment
for methamphetamine use, because of the
high rates of depression seen in this context.
Further research is needed to understand
whether methamphetamine use increases
the risk for major depression or whether the
high rates of depression in this population
are a consequence of transient drug-related
depressive symptoms. Finally, caution is
needed when diagnosing major depression
in the context of methamphetamine
dependence.
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2 Comparison of symptoms for major depression and substance-induced 
depression
Substance-induced 
depression (n = 176)
Major depression
(n = 158)
Periods of feeling sad, empty or depressed 79% 94%*
Loss of interest 97% 96%
Appetite change 96% 95%
Sleep disturbances 98% 97%
Slowness or restlessness 78% 79%
Fatigue or loss of energy 89% 94%
Feeling worthless or guilty 90% 80%†
Trouble concentrating 100% 100%
Suicidal ideation 61% 73%†
* P < 0.001, † P < 0.01 for difference between groups. ◆S54 MJA • Volume 195 Number 3 • 1 August 2011
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